Comparison of Efficacy of Azithromycin Alone vs Combination of Azithromycin and Probiotics in Management of Mild to Moderate Acne Vulgaris

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07384793

Enrollment

Registered

2026-02-03

Start date

2025-10-12

Completion date

2026-04-01

Last updated

2026-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne Vulgaris II or III Degree

Brief summary

The Goal of this Clinical trial is to compare the efficacy of oral azithromycin alone with combination therapy of oral azithromycin and probiotics to see is there any significant difference in outcome of two treatment modalities in mild to moderate acne vulgaris

Interventions

DRUGAzithromycin 250 MG Oral Capsule

The participants in this arm of study will receive only Oral Azithromycin 250mg on alternate day for 12 weeks to treat their Acne

DRUGAzithromycin 250 MG Oral Capsule Along with Oral Probiotics

The participants in this arm of study will receive only Oral Azithromycin 250mg on alternate day along with oral probiotics daily for 12 weeks to treat their Acne

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

15 Years to 35 Years

Healthy volunteers

Inclusion criteria

Participants with mild to moderate acne on basis of global acne assessment scale score of 2 or 3 and with 20 to 50 total lesion count will be included. \-

Exclusion criteria

History of active localized or generalized infection History of autoimmune disease History of other facial skin diseases/ excessive facial hair or scars History of using isotretinoin or oral contraceptive pills in past 6 months History of already using antibiotics for acne treatment History of facial cosmetic procedures within last 3 months History of allergy to drugs used in study History of using drugs that may interact with azithromycin Currently pregnant or lactating women

Design outcomes

Primary

Measure	Time frame	Description
Reduction of Acne Lesion Count as per Acne Global assessment scale	12 Weeks	The patients will be assessed before and after the treatment and their lesions will be counted .The Primary outcome that will be measured is the reduction of the lesion counts according to the Acne global Assessment scale The participants included will be with mild to moderate acne on basis of global acne assessment scale score of 2 or 3. The minimum Lesion count considered will be 20 and the Maximum will be 50. Lower is better Higher is worse.

Countries

Pakistan

Contacts

STUDY_CHAIRAyesha Naeem

Hayatabad Medical Complex Peshawar, KPK Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026